Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

nt.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: our ability to enroll approximately six patients at the 600mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter of 2008; Cadence's ability to enroll sufficient patients to complete the Omigard CLIRS trial; the adequacy of the CLIRS trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard; Cutanea's ability to manage, fund and advance omiganan for dermatological applications into Phase III, the adequacy of Cutanea's Phase II results for regulatory authorities to support advancing to Phase III; our ability to manage licensing opportunities; and our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on corporate collaborations; potential delays; uncertainties related to early stage of technology and product development; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our products; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns; the possibility that opportunities will arise that require more cash than presently anticipated and other uncertainties related to predictions of future cash requirements; and other risks and uncertainties which may not
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 The Kidney Cancer Association (KCA) has ... news magazine, Kidney Cancer News. , Bill Bro, KCA ... website maintained by an international news organization. When we began ... viewers.” , This month’s program highlights news of an enzyme ... in a recent study. Kidney Cancer News also presents a ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... 2014 While administrative claims and ... research for a relatively long period of time, ... the use of these ‘big data’ for comparisons ... combining today’s powerful computer technology with the plethora ... data’ holds significant promise for identifying optimal interventions ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Grace Launches New REVELERIS® Prep Purification System 2Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... 20, 2011 Masimo (Nasdaq: ... the clinical accuracy and value of its noninvasive and ... week at the Society of Critical Care Medicine ... The largest multi-professional critical care event of the year, ...
... Reportlinker.com announces that a new market research report ... Hospital Computer Tomography (CT) Census ... the most comprehensive European market report on the ... Mammography, R&F, Angiography, CT, MRI,) and radiology IT ...
... GPRO ) announced today that the Company will ... on Tuesday, February 15, 2011 at approximately 4:00 p.m. Eastern ... call with management at 4:30 p.m. ET.   ... accessed on the investors section of the Company,s web site ...
Cached Biology Technology:New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 2New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 3New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 4New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels 5Reportlinker Adds Hospital Computer Tomography (CT) Census 2Reportlinker Adds Hospital Computer Tomography (CT) Census 3Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call 2
(Date:7/30/2014)... The use of iodine-125 (125I) in cancer treatment ... dorsal root ganglia are critical for neural transmission ... Tengda Zhang and colleagues from Institute of Radiation ... that 125I could be implanted into rat dorsal ... pain. 125I seeds with different radioactivity (0, 14.8, ...
(Date:7/30/2014)... July 30, 2014 The Nano-Bio Manufacturing ... States Air Force Research Laboratory (AFRL), has awarded ... Binghamton University to develop electronics and ... The $425,000 project, with contributions from the University ... Electronics, Inc. ( Endicott, N.Y. ), ...
(Date:7/29/2014)... optical methods and applications for imaging and manipulation of ... neurosciences were the inspiration behind Neurophotonics , a ... for optics and photonics. , The first issue coincides ... United States, and a special section features articles that ... the impact that optics and photonics will have on ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3
... poorest regions could face severe crop losses in the next ... study by researchers at Stanford Universitys Program on Food Security ... in the Feb. 1 issue of the journal Science. ... agriculture for their livelihoods, said lead author David Lobell, a ...
... has some amazing properties. It is the only natural substance ... within the range of natural Earth temperatures. Its solid ... why ice floats. It can absorb a great deal of ... it move through roots and capillaries vital to maintaining ...
... process for medical devices does not involve the same ... change in order to improve health outcomes, say researchers ... The UCSF team analyzes the problem and proposes ... the January 2008 issue of the Journal of General ...
Cached Biology News:Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 4ASU professor helps solve mystery of glassy water 2ASU professor helps solve mystery of glassy water 3Analysis calls for medical device information to better serve patients and doctors 2Analysis calls for medical device information to better serve patients and doctors 3
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
...
Biology Products: